• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Panbela Therapeutics, Inc. - Common Stock (NQ:PBLA)

    N/A UNCHANGED
    Last Price Updated: 4:00 PM EST, Mar 6, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Panbela Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Panbela Announces Publication of Preclinical and Clinical Data Titled: Inhibition of Polyamine Biosynthesis Preserves β Cell Function in Type 1 Diabetes
    From Panbela Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
     
    Via Benzinga
    Panbela Announces Validation of European Patent in UK, Italy, Germany, France, and Spain for Claims of a Novel Process for the Production of SBP-101
    Patent developed in collaboration with Syngene International Ltd. 
    From Panbela Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's After-Market Session
     
    Via Benzinga
    Acceptance of Polyamine Inhibitor CAR-T Combination Abstract for Online Publication
    From Panbela Therapeutics, Inc.
    Via GlobeNewswire
    Panbela to Host Third Quarter 2023 Earnings Conference Call on November 9, 2023
    From Panbela Therapeutics, Inc.
    Via GlobeNewswire
    Panbela Announces Issuance of New Patent in China for Claims of a Novel Process for the Production of SBP-101
    Patent developed in collaboration with Syngene International Ltd. 
    From Panbela Therapeutics, Inc.
    Via GlobeNewswire
    Panbela to Present at the LD Micro Investor Conference
    From Panbela Therapeutics, Inc.
    Via GlobeNewswire
    Why Smith & Wesson Brands Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
    Gainers Impel Pharmaceuticals Inc. (NASDAQ: IMPL) rose 41.3% to $0.54 in pre-market trading after falling 4% on Thursday. 
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
    Pre-market stock movers are a hot topic worth checking out on Friday with a look at the biggest winners and losers today! 
    Via InvestorPlace
    Panbela Announces Issuance of New Patent in Chile for Claims of a Novel Process for the Production of Flynpovi
    Patent developed in collaboration with Sanofi 
    From Panbela Therapeutics, Inc.
    Via GlobeNewswire
    Panbela to Present at H.C. Wainwright 25th Annual Global Investment Conference
    From Panbela Therapeutics, Inc.
    Via GlobeNewswire
    Stocks That Hit 52-Week Lows On Wednesday
      Wednesday's session saw 150 companies set new 52-week lows. 
    Via Benzinga
    Panbela Announces Issuance of New Patent in Europe for Claims of a Novel Process for the Production of SBP-101
    Patent developed in collaboration with Syngene International Ltd. 
    From Panbela Therapeutics, Inc.
    Via GlobeNewswire
    Panbela to Host Second Quarter 2023 Earnings Conference Call on August 10, 2023
    From Panbela Therapeutics, Inc.
    Via GlobeNewswire
    Panbela Opens Enrollment in UK and Germany for Aspire Trial in Pancreatic Cancer, All Countries/Regions in the Aspire Trial are Now Open and Actively Enrolling
    Interim Data Analysis anticipated in Early 2024 
    From Panbela Therapeutics, Inc.
    Via GlobeNewswire
    Earnings Scheduled For August 10, 2023
    Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million. 
    Via Benzinga
    Nasdaq Moves Lower; US Crude Oil Inventories Decline Less Than Projected
    U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite moving lower on Wednesday. The Dow traded up 0.31% to 35,058.78 while the NASDAQ fell 0.21% to 14,323.99. The S&P 500, also... 
    Via Benzinga
    Why Amarin Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Gainers Biodexa Pharmaceuticals Plc (NASDAQ: BDRX) rose 43% to $6.91. 
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Intraday Session
     
    Via Benzinga
    Why Are Panbela Therapeutics Shares Trading Higher Today?
    Panbela Therapeutics Inc (NASDAQ: PBLA) shares are trading higher after the company divested certain assets in its eflornithine pediatric neuroblastoma program to US WorldMeds 1 (USWM), a... 
    Via Benzinga
    Crude Oil Up 1%; M&T Bank Posts Upbeat Q2 Results
    U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 0.5% on Wednesday. The Dow traded up 0.53% to 35,137.16 while the NASDAQ rose 0.48% to 14,422.74. The S&P 500,... 
    Via Benzinga
    Dow Rises Over 100 Points; Goldman Sachs Earnings Miss Estimates
    U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.37% to 35,082.94 while the NASDAQ rose... 
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
     
    Via Benzinga
    Panbela Therapeutics to Receive a Total Up to $9.5 Million for Divestiture of Assets within Eflornithine (DFMO) Pediatric Neuroblastoma Program to US WorldMeds
    From Panbela Therapeutics, Inc.
    Via GlobeNewswire
    Panbela Announces Issuance of New Patent in Australia Patent is for Claims of a Novel Process for the Production of SBP-101
    Patent developed in collaboration with Syngene International Ltd. 
    From Panbela Therapeutics, Inc.
    Via GlobeNewswire
    Panbela's Diverse Pipeline Is Encouraging Amidst Challenges In Pancreatic Cancer Therapy: Analyst
    Panbela Therapeutics Inc (NASDAQ: PBLA) said that the independent Data Safety Monitoring Board (DSMB) of the Phase 3 ASPIRE trial for patients with untreated metastatic pancreatic ductal adenocarcinoma... 
    Via Benzinga
    Panbela Announces Preliminary Safety Analysis for ASPIRE Trial
    From Panbela Therapeutics, Inc.
    Via GlobeNewswire
    Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In July
    The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
    Via Benzinga
    BioMedNewsBreaks – Panbela Therapeutics Inc. (NASDAQ: PBLA) Closes on Public Offering Totaling About $8.5M
    Via Investor Brand Network
    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.